Human Albumin Baxalta

Human Albumin Baxalta is a pharmaceutical product that contains the active ingredient human serum albumin. It is supplied as an intravenous solution, with the specific strength not disclosed in the public label. The preparation is classified as a plasma protein and is marketed in the European Union. It is a prescription‑only medication used by health‑care professionals to manage conditions requiring plasma volume expansion in clinical practice.

Human Albumin Baxalta is indicated for therapeutic situations where restoration of intravascular volume and oncotic pressure is required.

- Treatment of hypovolemia due to acute blood loss, dehydration, or fluid shifts. - Management of patients in circulatory shock when plasma expansion is needed. - Supportive care for severe burns to replace lost plasma proteins. - Correction of hypoalbuminemia associated with liver disease, nephrotic syndrome, or malnutrition. - Adjunct in cardiac surgery or liver transplantation to maintain hemodynamic stability.

Adverse reactions to Human Albumin Baxalta are generally related to its protein nature and the intravenous route of administration.

Common: - Mild fever, chills, or flushing during or shortly after infusion. - Transient hypotension or hypertension that resolves without intervention. - Headache, nausea, or mild abdominal discomfort. - Localized erythema or urticaria at the infusion site. - Mild itching or skin rash that resolves after the infusion. - Transient increase in serum calcium due to albumin binding.

Serious: - Anaphylactic or severe allergic reactions, including bronchospasm and angioedema. - Volume overload leading to pulmonary edema, especially in patients with cardiac dysfunction. - Hemolysis or renal impairment associated with contaminated plasma products. - Transmission of infectious agents, although rare with modern manufacturing.

When prescribing Human Albumin Baxalta, clinicians should evaluate patient history and monitor for potential complications related to volume status and protein infusion.

- Assess cardiac function before administration to avoid volume overload. - Verify absence of known hypersensitivity to human albumin or plasma derivatives. - Use caution in patients with renal impairment or severe liver disease. - Monitor vital signs and fluid balance during and after infusion. - Adjust infusion rate in individuals prone to hypotension or hypertension. - Avoid concurrent use of other plasma expanders unless clinically justified.

Human Albumin Baxalta may interact with other agents that affect fluid balance, coagulation, or immune response, requiring careful consideration of concomitant therapy.

Avoid: - Simultaneous infusion of high‑dose diuretics that could precipitate rapid intravascular volume shifts. - Co‑administration with other plasma protein products unless specifically indicated clinically.

Use with caution: - Vasopressors or inotropes, as changes in vascular tone may alter the response to volume expansion. - Anticoagulants, because altered plasma protein levels can affect drug binding and monitoring. - Immunosuppressive agents, given the potential for enhanced allergic reactions. - Renal replacement therapies, where albumin removal may reduce therapeutic effect.